QYUNS-B Reports Stable Share Capital and Confirms Public Float Compliance for March 2026

Bulletin Express04-09

Qyuns Therapeutics Co., Ltd. (QYUNS-B) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 9 April 2026, covering the month ended 31 March 2026.

The company’s authorised and registered share capital remained unchanged at 227.07 million ordinary H shares, each with a par value of RMB 1, translating into total authorised capital of RMB 227.07 million.

Issued share metrics were also stable: • Issued shares (excluding treasury): 224.57 million • Treasury shares: 2.50 million • Total issued shares: 227.07 million No new shares were issued, cancelled, or repurchased during the reporting month.

QYUNS-B affirmed that it satisfied the Main Board’s minimum public float requirement of 25 percent as of 31 March 2026.

The filing states there were no outstanding share options, warrants, convertible securities, or other agreements that could lead to further share issuance, and no movements in Hong Kong Depositary Receipts.

All requisite confirmations under Main Board Rule 13.25C were provided by Board Secretary and Joint Company Secretary Hu Yanbao, indicating full compliance with listing and regulatory obligations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179832135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179832135","market":"us","top_or_hot":-1,"title":"QYUNS-B Reports Stable Share Capital and Confirms Public Float Compliance for March 2026","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 9 April 2026, covering the month ended 31 March 2026.</p>\n<p>The company’s authorised and registered share capital remained unchanged at 227.07 million ordinary H shares, each with a par value of RMB 1, translating into total authorised capital of RMB 227.07 million.</p>\n<p>Issued share metrics were also stable:\n• Issued shares (excluding treasury): 224.57 million  \n• Treasury shares: 2.50 million  \n• Total issued shares: 227.07 million  \nNo new shares were issued, cancelled, or repurchased during the reporting month.</p>\n<p>QYUNS-B affirmed that it satisfied the Main Board’s minimum public float requirement of 25 percent as of 31 March 2026.</p>\n<p>The filing states there were no outstanding share options, warrants, convertible securities, or other agreements that could lead to further share issuance, and no movements in Hong Kong Depositary Receipts.</p>\n<p>All requisite confirmations under Main Board Rule 13.25C were provided by Board Secretary and Joint Company Secretary Hu Yanbao, indicating full compliance with listing and regulatory obligations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B Reports Stable Share Capital and Confirms Public Float Compliance for March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B Reports Stable Share Capital and Confirms Public Float Compliance for March 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 9 April 2026, covering the month ended 31 March 2026.</p>\n<p>The company’s authorised and registered share capital remained unchanged at 227.07 million ordinary H shares, each with a par value of RMB 1, translating into total authorised capital of RMB 227.07 million.</p>\n<p>Issued share metrics were also stable:\n• Issued shares (excluding treasury): 224.57 million  \n• Treasury shares: 2.50 million  \n• Total issued shares: 227.07 million  \nNo new shares were issued, cancelled, or repurchased during the reporting month.</p>\n<p>QYUNS-B affirmed that it satisfied the Main Board’s minimum public float requirement of 25 percent as of 31 March 2026.</p>\n<p>The filing states there were no outstanding share options, warrants, convertible securities, or other agreements that could lead to further share issuance, and no movements in Hong Kong Depositary Receipts.</p>\n<p>All requisite confirmations under Main Board Rule 13.25C were provided by Board Secretary and Joint Company Secretary Hu Yanbao, indicating full compliance with listing and regulatory obligations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1179832135","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179832135","pubTimestamp":1775731680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 9 April 2026, covering the month ended 31 March 2026. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"QYUNS-B报告股本稳定并确认2026年3月公众持股量合规性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 9 April 2026, covering the month ended 31 March 2026.\nThe company’s authorised and registered share capital remained unchanged at 227.07 million ordinary H shares, each with a par value of RMB 1, translating into total authorised capital of RMB 227.07 million.\nIssued share metrics were also stable:\n• Issued shares (excluding treasury): 224.57 million  \n• Treasury shares: 2.50 million  \n• Total issued shares: 227.07 million  \nNo new shares were issued, cancelled, or repurchased during the reporting month.\nQYUNS-B affirmed that it satisfied the Main Board’s minimum public float requirement of 25 percent as of 31 March 2026.\nThe filing states there were no outstanding share options, warrants, convertible securities, or other agreements that could lead to further share issuance, and no movements in Hong Kong Depositary Receipts.\nAll requisite confirmations under Main Board Rule 13.25C were provided by Board Secretary and Joint Company Secretary Hu Yanbao, indicating full compliance with listing and regulatory obligations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179832135","isCrawlerRequest":true}